7-[methyl-(2-sulfanylidene-1H-[1,3]thiazolo[5,4-b]pyridin-5-yl)amino]-7-oxoheptanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7-[methyl-(2-sulfanylidene-1H-[1,3]thiazolo[5,4-b]pyridin-5-yl)amino]-7-oxoheptanoic acid
• 化学式: C₁₄H₁₇N₃O₃S₂
• 分子量: 339.4
• InChiKey: MQIUUMXYQOUKFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  140
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
  申请人：——

  公开号：US20040092503A1

  公开（公告）日：2004-05-13

  The present invention relates to methods of treatment of certain metabolic diseases, and to novel compounds and their prodrugs, and/or pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds useful in treating such diseases. In particular, this invention relates to the use of novel compounds and compositions for treatment of cardiovascular diseases, diabetes, cancers, acidosis, and obesity through the inhibition of malonyl-CoA decarboxylase (MCD). These compounds have the formulae (I) and (II), wherein Y, C, R 1 , R 2 , R 6 , and R 7 are defined herein. 1

  本发明涉及治疗某些代谢性疾病的方法，以及新型化合物及其前药和/或药物可接受的盐，包含这些化合物的制药组合物用于治疗这些疾病。特别是，本发明涉及使用新型化合物和组合物通过抑制丙酰辅酶A脱羧酶（MCD）治疗心血管疾病，糖尿病，癌症，酸中毒和肥胖症。这些化合物的式子为（I）和（II），其中Y，C，R1，R2，R6和R7在此定义。
• AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1370260A2

  公开（公告）日：2003-12-17
• [EN] AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS<br/>[FR] AZOLES EN INHIBITEURS DE LA DÉCARBOXYLASE DES MALONYL-COA, CONVENANT COMME MODULATEURS MÉTABOLIQUES
  申请人：CHUGAI PHARMACEUTICAL CO LTD

  公开号：WO2002066035A2

  公开（公告）日：2002-08-29

  The present invention relates to methods of treatment of certain metabolic diseases, and to novel compounds and their prodrugs, and/or pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds useful in treating such diseases. In particular, this invention relates to the use of novel compounds and compositions for treatment of cardiovascular diseases, diabetes, cancers, acidosis, and obesity through the inhibition of malonyl-CoA decarboxylase (MCD). These compounds have the formulae (I) and (II), wherein Y, C, R1, R2, R6, and R7 are defined herein.